DCIS margins <2 mm not tied to recurrence except age <50

Editor's Pick: Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study (Journal of Clinical Oncology, 2026)
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning first-line advances and immune biology in thoracic cancers, a run of breast cancer studies that challenge how we operate and how we combine targeted agents, and a broader set on vaccines, biomarker-driven melanoma therapy, and the health-system side of cancer care. Let's dive in.

We'll start with lung cancer.
This week's papers:
• Phase III Trials Test First-Line Options in Advanced NSCLC. — Cancer Discovery 2026 (pubmed.ncbi.nlm.nih.gov/42755291)
• Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42754095)
• Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42766806)
• Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study. — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42765908)
• Vaccines for Cancer: A Translational Science Review. — JAMA 2026 (pubmed.ncbi.nlm.nih.gov/42766303)
• Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42771837)
• Precision prevention and early detection: framework for a new clinical cancer control pathway. — The Lancet 2026 (pubmed.ncbi.nlm.nih.gov/42759527)
• γδ T cells modulate anti-tumor immunity in small cell lung cancer. — Cancer Cell 2026 (pubmed.ncbi.nlm.nih.gov/42759517)
• Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma. — Nature Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42754728)
• Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42758960)
Listen at AudioScholar (audioscholar.cc/episode/636a8quyhc)